Products & Services · Transaction price

Research Services Obligation — Transaction price

Alnylam Pharmaceuticals Research Services Obligation — Transaction price remained flat by 0.0% to $100.50M in Q1 2026 compared to the prior quarter.

Analysis

StatementSegment
First reportedQ2 2019
Last reportedQ1 2026
Metric ID: alny_segment_research_services_obligation_transaction_price

Historical Data

14 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q4 '23Q2 '25Q3 '25Q4 '25Q1 '26
Value$200.70M$200.70M$200.68M$200.68M$215.60M$215.68M$215.68M$205.68M$305.68M$305.70M$100.50M$100.50M$100.50M$100.50M
QoQ Change+0.0%-0.0%+0.0%+7.4%+0.0%+0.0%-4.6%+48.6%+0.0%-67.1%+0.0%+0.0%+0.0%
YoY Change+7.4%+7.5%+7.5%-4.6%+41.7%
Range$100.50M$305.70M
CAGR-19.2%
Avg YoY Growth+11.9%
Median YoY Growth+7.5%
Current Streak3 quarters growth

Frequently Asked Questions

What is Alnylam Pharmaceuticals's research services obligation — transaction price?
Alnylam Pharmaceuticals (ALNY) reported research services obligation — transaction price of $100.50M in Q1 2026.